Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody huJ591

Known as: MOAB huJ591, huJ591 
A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers
Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).
287 Background: There is a pressing need for improved imaging biomarkers to identify disease distribution and response in both… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Purpose: Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Jeremy C. Durack, Serge Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
PurposeGiven the bone tropism of prostate cancer, conventional imaging modalities poorly identify or quantify metastatic disease… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2013
Review
2013
Prostate-specific membrane antigen-based imaging.
Prostate cancer (CaP) is the most common noncutaneous malignancy affecting men in North America. Despite significant efforts… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 2
Is this relevant?
2005
2005
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Prostate specific membrane antigen (PSMA) is a well-characterized glycoprotein overexpressed on the surface of prostate cancer… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice
Prostate specific membrane antigen (PSMA), expressed by virtually all prostate cancers is an ideal target for targeted therapy of… Expand
Is this relevant?
Review
2003
Review
2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
PURPOSE Prostate specific membrane antigen (PSMA) is a cell surface peptidase highly expressed by malignant prostate epithelial… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE